About: Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Naveed Sattar et al published 2007 in Arthritis and Rheumatism

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у 2007 (uk) article scientifique publié en 2007 (fr) im Jahr 2007 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Naveed Sattar et al published 2007 in Arthritis and Rheumatism (en)
publication date	wds:Q57232023-ECA06836-22BA-4461-BDB4-2C1B1FD840DA
publication date	2007-01-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q57232023-53C32875-B771-446C-957A-4AAC8A459E16
cites work	Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies
author name string	wds:Q57232023-372FE34A-CC65-48EB-BB95-CE177163F415 wds:Q57232023-421FBDAC-0246-47FF-A659-2D7D145C41C5 wds:Q57232023-45677477-D54D-477E-B7CE-BA83AEB7227C wds:Q57232023-75622650-39C9-4D04-AF0F-59B35C462B9F wds:Q57232023-AA9E693E-52AC-4DE0-83DA-BB1C1DE51CA8
author name string	David Kane Gordon Lowe Lynne Cherry Iain B. McInnes Philippa Crompton
rdfs:label	Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (en) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (nl)
skos:prefLabel	Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (en) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (nl)
name	Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (en) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (nl)
author	wds:Q57232023-8A6E473A-07D5-4D35-98B7-0DD2F9298A8E
author	Naveed Sattar
title	wds:Q57232023-2FA5CF4B-1E96-48F8-9C76-1F10B2C7CA7B
title	Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study (en)
page(s)	wds:Q57232023-AAB79A1F-8533-426B-9ADB-1D178FAC9937
page(s)	831-839
instance of	wds:Q57232023-FA99FE09-F3C2-4A37-8D24-9A3D313AC511
instance of	scholarly article
main subject	wds:Q57232023-0D6E912F-ABD4-474F-B673-E95B4EC6D543 wds:Q57232023-22A35CDF-B54E-4F8C-B617-18F67F0327D2 wds:Q57232023-40DAA284-B71F-4D46-95A4-8E6CCD8EE9DE wds:Q57232023-65169F9C-1464-440D-B883-5D4E9654FC3C wds:Q57232023-72DE1972-B633-4011-9F51-75960521F843
main subject	rheumatology placebo psoriatic arthritis blood circulation immunology
PubMed ID	wds:Q57232023-66059E78-E007-4493-A475-B7D0A50E9715
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17328057
PubMed ID	17328057
published in	wds:Q57232023-531636DA-31C7-45B0-ABEF-1488F5711AE0
published in	Arthritis and Rheumatism
issue	wds:Q57232023-1EFDEB21-F49F-478F-83D3-00471726CD00
volume	wds:Q57232023-19428BA8-94CF-4B3E-B12F-7081F5888543
issue	3
volume	56
DOI	wds:Q57232023-ED73C29D-8C97-4AE3-8C1F-725E615190A0
DOI	http://dx.doi.org/10.1002/ART.22447
DOI	10.1002/ART.22447
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57232023
is cites work of	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. [Psoriasis, metabolic syndrome and its components] Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Role for TNF in atherosclerosis? Lessons from autoimmune disease Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Cardiovascular risk in patients with psoriatic arthritis Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease Psoriasis is not a useful independent risk factor for cardiovascular disease Plasma homocysteine is elevated in COPD patients and is related to COPD severity The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases Atherosclerosis in psoriatic disease: latest evidence and clinical implications Lipid disturbances in psoriasis: an update. Potential role of tumor necrosis factor-α in downregulating sex hormone-binding globulin Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis Prevention of stroke in rheumatoid arthritis. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Cardiovascular risk in psoriatic arthritis - a cross-sectional study Molecular Mechanism of TNFα-Induced Down-Regulation of SHBG Expression. Homocysteine may involve in the pathogenesis of Behcet's disease by inducing inflammation Managing comorbid disease in patients with psoriatic arthritis Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy Homocysteine plasma levels in psoriasis patients: our experience and review of the literature Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Psoriatic arthritis: current topics Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function. Management of Hidradenitis Suppurativa in Patients with Metabolic Comorbidities What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials The treatment of psoriatic arthritis and inflammatory spondylitis
is cites work of	wds:Q37130144-DFC16BD7-1B51-47FF-90AE-E932F6AAD063

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software